| Research |
|
|
|
|
Online articles: Setting benchmarks in the treatment of invasive bladder cancer from the 'Urologic Oncology' journal, 2007 Volume 25, Issue 1, Pages 57-65 (January 2007) Surgical benchmarks for the treatment of invasive bladder cancer Eila C. Skinner, John P. Stein, Donald G. Skinner Benchmarks achieved in the delivery of radiation therapy for muscle-invasive bladder cancer John J. Coen, Anthony L. Zietman, Donald S. Kaufman, William U. Shipley WebCafe's Picks This e-mail address is being protected from spam bots, you need JavaScript enabled to view it Sept. '07 - NCI approved chemosensitivity testing for bladder cancer drugs and personal response - a valuable tool Coxen- http://www.coxen.org/ "It is hoped that COXEN may prove to be a valuable tool in the treatment of cancer and the discovery of novel agents for specific cancer types. Accurate compound pre-screening could also substantially reduce the failure rates in clinical trials, in addition to being a potential strategy to personalize cancer therapy." Coxen genetic assays can predict response to cisplatin, Taxol, Taxotere, Tamoxifen and possibly more chemotherapy drugs. Blood tests for bladder cancer on the horizon? Jan. 2006: Profiling bladder cancer using targeted antibody arrays.The Tumor Markers Group published an article in the American Journal of Pathology about the progress being made in the field of serum (blood) markers to aid both diagnois and prognosis. The authors stated that serum protein profiles measured by an antibody array discriminated bladder cancer patients from controls correctly at the rate of 93.7%. A second independent antibody array containing revealed that protein profiles can predict information by stratifying patients with bladder tumors based on their overall survival. "In addition, serum proteins, such as c-met, that were top ranked at identifying bladder cancer patients were associated with pathological stage, tumor grade, and survival when validated by immunohistochemistry of tissue microarrays containing bladder tumors. This study provides experimental evidence for the use of several integrated technologies strengthening the process of biomarker discovery. Serum protein profiles obtained by antibody arrays represent comprehensive means for bladder cancer diagnosis and clinical outcome stratification, which could potentially assist in selection of cancer patients who would benefit from early, individualized therapeutic intervention." PubMed Abstract From the Division of Molecular Pathology* and Computational Biology Center,{dagger} Memorial Sloan-Kettering Cancer Center, New York, New York; The Van Andel Institute,§ Grand Rapids, Michigan; and the Laboratorio de Microarrays,{ddagger} Center for Genomic Regulation, Barcelona, SpainSanchez-Carbayo M, Socci ND, Lozano JJ, Haab BB, Cordon-Cardo C.Tumor Markers Group, Molecular Pathology Programme Centro Nacional de Investiga-ciones Oncologicas, Melchor Fernandez Almagro 3, E-28029 Madrid, Spain. American Journal of Pathology. 2006;168:93-103. © 2006 American Society for Investigative Pathology EDRN: Early Detection Network - Scientists Begin Validation NCI Study of Test to Detect Recurrence of Bladder Cancer. Results due in 2007: By examining genetic changes in DNA obtained through urine samples, the test, if successfully validated, will provide a sensitive and non-invasive method of screening for bladder cancer recurrence. A three-year study to validate a test to detect the recurrence of bladder cancer has been initiated by the National Cancer Institute (NCI), at 13* centers across the United States and Canada. The test - which examines genetic changes in DNA obtained through urine samples - if successfully validated, will provide a sensitive and non-invasive method of screening for bladder cancer recurrence. This is the first study study testing a marker for bladder cancer, and the first Phase III study for an Early Detection Research Network- EDRN-created test. The leading investigator and the coordinator of this study is Dr. Mark Schoenberg, form the James Buchanan Brady Urological Institute, Johns Hopkins University, Baltimore, MD.. http://www.nci.nih.gov/newscenter/pressreleases/EDRNvalidation * The institutions and principal investigators include: Johns Hopkins University, James Buchanan Brady Urological Institute, (Mark Schoenberg, M.D.) University of Alabama-Birmingham; Birmingham, Ala. (Donald Urban, M.D.) Baylor College of Medicine; Houston, Texas (Seth Lerner, M.D.) University of Chicago Center for Advanced Medicine; Chicago, Ill. (Gary Steinberg, M.D.) Carolina Urologic Research Center; Myrtle Beach, S.C. (Neal Shore, M.D.) MD Anderson Cancer Center; Houston, Texas (Colin Dinney, M.D.) Memorial Sloan Kettering; New York, N.Y. (Guido Dalbagni, M.D.) University of Michigan; Ann Arbor, Mich. (Cheryl Lee, M.D.) University of Rochester; Rochester, N.Y. (Edward Messing, M.D.) Stanford University; Stanford, Calif. (Joseph Presti Jr., M.D.) University of Texas Health Science Center; San Antonio, Texas (Joseph Basler, M.D., Ph.D.) University of Toronto; Toronto, Ontario (Laurence Klotz, M.D.) Washington University; St. Louis, Mo. (Adam Kibel, M.D.) Perspectives in Bladder Cancer; 2003-Euro/American conference specifically addressing bladder cancer-Lectures and presentations given by expert urologists, oncologists, and pathologists from the USA and Europe focused on techniques and cost-efficacy of screening, intravesical therapy, the management of muscle invasive bladder cancer, the role of radiation and chemotherapy, new drug regimens and innovative approaches on the horizon. The health economics of bladder cancer - Read the Hard Facts here What's in the Pipeline for bladder cancer? Innovative delivery system "Electromotive Drug Administration" which improves response rates for those with non-invasive blc, undergoing a combination of BCG and Mitomycin C, read here Abstracts of interest- Preliminary European results of local microwave hyperthermia and chemotherapy treatment in intermediate or high risk superficial transitional cell carcinoma of the bladder. Van Der Heijden AG, Kiemeney LA, Gofrit ON, Nativ O, Sidi A, Leib Z, Colombo R, Naspro R, Pavone M, Baniel J, Hasner F, Witjes JA. Dep't of Urology, University Medical Centre Nijmegen, The Netherlands Eur Urol. 2004 Jul;46(1):65-72. A
single immediate postoperative instillation of chemotherapy decreases
the risk of recurrence in patients with stage Ta T1 bladder cancer: a
meta-analysis of published results of randomized clinical trials. Sylvester
RJ, Oosterlinck W, van der Meijden AP. European Organization for the Research
and Treatment of Cancer Data Center, Brussels, the Universitair Ziekenhuis
Gent, Gent, Belgium; J Urol. 2004 Jun;171(6 Pt 1):2186-90, quiz 2435. _______________________________________________________ Tolerance
of radiotherapy and chemotherapy in elderly patients with bladder cancer.Goffin
JR, Rajan R, Souhami L.McGill University Health Centre, Montreal General
Hospital, Montreal, Quebec, Canada.Am J Clin Oncol. 2004 Apr;27(2):172-7. ### LINK NOT FOUD ###Pathologic evaluation of radical cystectomy specimens. Herr HW, Faulkner JR, Grossman HB, Crawford ED. Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, New York. Cancer. 2004 Jun 1;100(11):2470-5. Impact
of transurethral resection of bladder tumor: analysis of cystectomy specimens
to evaluate for residual tumor. Lee SE, Jeong IG, Ku JH,
Kwak C, Lee E, Jeong JS. Department of Urology, Seoul National University
College of Medicine, Seoul, South Korea. Urology. 2004 May;63(5):873-7;
discussion 877 The
proteasome inhibitor bortezomib synergizes with gemcitabine to block the
growth of human 253JB-V bladder tumors in vivo. Kamat AM,
Karashima T, Davis DW, Lashinger L, Bar-Eli M, Millikan R, Shen Y, Dinney
CP, McConkey DJ.Department of Urology, University of Texas MD Anderson
Cancer Center, Houston, TX, USA. Mol Cancer Ther. 2004 Mar;3(3):279-90. Integrating basic science and clinical research in bladder cancer:
update from the first bladder Specialized Program of Research Excellence
(SPORE). Sept, 2004 Summary: Targeted therapy against epidermal
growth factor receptor has become one of the primary focuses of the genitourinary
SPORE in bladder cancer. The SPORE grant scheme is designed to encourage
rapid development of new and innovative cancer research in areas of high
priority, in this case bladder cancer. The SPORE has facilitated the advancement
of novel epidermal growth factor receptor-targeted therapy, such as the
monoclonal antibody IMC-225 and the tyrosine kinase inhibitor ZD1839 (Iressa),
from the laboratory to clinical trials. The integration of these new biological
agents in combination with chemotherapy, in order to abrogate the progression
of advanced bladder cancer, is the prime directive of our current phase
II Iressa/docetaxel trial. Abstract Cancer Research Portfolio, from the NCI, see the current 325 projects currently underway for bladder cancer NCI ClinicalTrials;
http://cancer.gov/clinicaltrials/ National Cancer Institute http://www.cancer.gov/cancertopics/types/bladder NCI's primary web site; contains information about the Institute and its programs. Also includes news, upcoming events, educational materials, and publications for patients, the public, and the mass media Entrez-Pub
Med http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed The European Ass. of Urology: Guidelines for treatment of bladder cancer The European
School of Urology : Management of Superficial Bladder Cancer Online
course |